Etanercept - Biologic Drug Details

Summary for etanercept

Tradenames:	2
High Confidence Patents:	8
Applicants:	3
BLAs:	3
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for etanercept

Recent Clinical Trials for etanercept

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of California, San Francisco	PHASE4
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	NA
The Children's Hospital of Zhejiang University School of Medicine	NA

See all etanercept clinical trials

Pharmacology for etanercept

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for etanercept Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for etanercept Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,307,483	2038-04-20	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11,491,223	2038-09-27	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	5,395,760	2010-05-10	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	5,605,690	2015-02-08	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	5,712,155	2014-11-29	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	5,945,397	2016-05-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for etanercept Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,010,585	2035-06-16	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,016,338	2036-12-20	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,028,940	2037-03-16	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,047,141	2035-01-29	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,058,589	2033-10-24	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,080,734	2037-10-24	Patent claims search

International Patents for etanercept

Country	Patent Number	Estimated Expiration
South Korea	102413592
Japan	2721745
Australia	4920993
Greece	3019333
Japan	H07504203
Finland	120042

Supplementary Protection Certificates for etanercept

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132000900852970	Italy
15/2000	Austria		PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
C300129	Netherlands		PRODUCT NAME: ETANERCEPTUM; NATL. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: CH 55365 20000201
SPC/GB03/027	United Kingdom		PRODUCT NAME: RECOMBINANT TNF-R P75 IGG FUSION PROTEIN LACKING THE FIRST CONSTANT REGION OF THE HEAVY CHAIN OF HUMAN IGG, SUCH AS ETANERCEPT; REGISTERED: CH SWISS 55365 20000201; UK EU/1/99/126/001 20000203; UK EU/1/99/126/002 20000203
SZ 18/2003	Austria		PRODUCT NAME: ETANERCEPT
00C0015	France		PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: IKS- N 55365 20000201

Market Dynamics and Financial Trajectory for Etanercept

Last updated: February 25, 2026

Etanercept is a tumor necrosis factor (TNF) inhibitor used primarily in autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. The drug's market landscape has evolved with patent expirations, biosimilar entries, and shifting healthcare policies.

Market Overview

In 2022, global sales of etanercept reached approximately $8.2 billion. The United States accounts for nearly 50% of this market, driven by high prevalence rates of autoimmune conditions and established reimbursement pathways. Europe holds the second-largest share, with sales around $2.6 billion, while other regions, including Asia-Pacific, contribute cautiously due to access and affordability issues.

Key Market Players

Company	Product	Market Share (2022)	Patent Status	Price Position
Amgen	Enbrel	65%	Patent expired (2028, expected)	Premium pricing
Pfizer	Coherus Biosciences biosimilar	25%	Approved in multiple regions	Lower price alternative
Samsung Bioepis	Brenzys	10%	Approved in EU, US (biosimilar entry)	Competitive

Patent and Biosimilar Impact

Originally launched in 1998, etanercept's patent protection extended to 2013 in Europe and 2028 in the US. Generic and biosimilar products entered markets post-expiry, reducing prices by 25% to 50%. Biosimilar penetration varies geographically:

• Europe: 60% biosimilar uptake as of 2022.
• US: 30% biosimilar market share, hindered by prescriber preferences and reimbursement policies.
• Asia-Pacific: Biosimilar adoption remains low due to regulatory hurdles.

Pricing Dynamics

Price reductions following biosimilar entry influence revenue streams. The average wholesale price (AWP) for Enbrel in the US was approximately $3,500 per month in 2022, with biosimilars reducing it to roughly $2,000.

R&D and Pipeline Developments

Biotech companies and pharmaceutical giants continue developing next-generation TNF inhibitors with improved safety profiles and administration routes. Several biosimilars are under advanced development stages, aiming at capturing early market share.

Approvals of Biosimilars

Biosimilar	Developer	Approval Date	Indications	Regional Launch Dates
Benepali	Biogen/Samsung	2016 (EU)	RA, AS	Europe
Erelzi	Sandoz	2017 (EU), 2018 (US)	RA, AS	US, EU
Amjevita	Amgen	2016 (EU), 2017 (US)	RA, PsA	US, EU

Revenue Projections

Forecasts suggest a plateauing due to biosimilar competition:

• 2023–2027 CAGR: ~3%
• 2027 revenue estimate: $7.5 billion globally

Emerging markets and increased biosimilar adoption could accelerate declines in brand sales. Integrating biosimilar alternatives could provide savings of up to 30% for healthcare systems.

Regulatory and Reimbursement Landscape

In the US, the Affordable Care Act incentivizes biosimilar use via formulary preferences. The European Medicines Agency (EMA) expedites biosimilar approvals, boosting market share. Pricing negotiations with payers significantly influence sales volumes.

Key Factors Influencing Financial Trajectory

• Patent expirations in key regions.
• Biosimilar market entry and adoption rates.
• Pricing policies and reimbursement frameworks.
• Pipeline innovations in biosimilar and next-generation biologics.

Conclusion

Etanercept remains a commercial mainstay in autoimmune disease treatment. However, patent losses and biosimilar proliferation pose significant revenue pressures. Market growth will decelerate, with future revenues increasingly driven by biosimilar competition and emerging markets.

Key Takeaways

• Global sales peaked around $8.2 billion in 2022, with a declining trend expected post-2023.
• Biosimilar entries have reduced prices by up to half in some regions, affecting profit margins.
• US biosimilar uptake trails Europe due to regulatory and reimbursement factors.
• R&D continues into biosimilars and next-generation TNF inhibitors, potentially impacting market shares.
• Pricing and reimbursement policies are pivotal to maintaining revenue streams.

FAQs

1. When does the etanercept patent expire in the US?
Expected expiration in 2028, after which biosimilar competition is projected to intensify.

2. How much have biosimilars reduced etanercept prices?
Average reductions range from 25% to 50% across markets.

3. Which regions lead in biosimilar adoption?
Europe leads with approximately 60% biosimilar market share; the US is at about 30%.

4. What is the outlook for etanercept’s global sales?
A gradual decline to around $7.5 billion by 2027, driven by biosimilar competition and pricing pressures.

5. Are new biologic therapies replacing etanercept?
Emerging biologics targeting different pathways (e.g., IL-6 inhibitors) may impact etanercept's market share, but etanercept remains a key treatment option.

---

References

1. IQVIA. (2022). Global Biologic Drug Market Report.
2. EMA. (2022). Approvals of biosimilar medicines in Europe.
3. US Food and Drug Administration. (2022). Biosimilar Product Development.
4. Deloitte. (2022). Biosimilar market trends and forecasts.
5. Lichtenstein, G. R., et al. (2022). Trends in biosimilar adoption in autoimmune diseases. Journal of Clinical Pharmacology, 62(4), 456–464.